Ambrx Biopharma, Inc. (NASDAQ: AMAM): Investor Relations Program

Ambrx is a clinical-stage biopharmaceutical company using an expanded genetic code technology platform to discover and develop next-generation antibody drug conjugates (ADCs) and other engineered therapies to modulate the immune system.

LifeSci embarked on a journey with Ambrx, beginning in November 2022, with a shared vision of enhancing its market presence and investor relations landscape. Over the course of this partnership, LifeSci’s approach was multifaceted, aiming not just to amplify Ambrx’s visibility, but to weave a narrative that resonated deeply with investors and stakeholders alike.


Recognizing the immense potential within Ambrx, LifeSci orchestrated a series of meticulously planned engagements.

• Introduced Ambrx to 70 High-Net-Worth retail investors through bespoke events, including the notable “Lunch with LifeSci,” fostering genuine conversations and deeper understanding of Ambrx’s value proposition.

• Hosted two impactful Key Opinion Leader (KOL) Events, attracting top-tier institutional investors and industry giants like Johnson & Johnson, underscoring Ambrx’s credibility and potential.

• Organized the In-Person KOL Event at the European Society for Medical Oncology (ESMO) in Madrid, drawing over 200 attendees and highlighting global recognition garnered by Ambrx under LifeSci’s guidance. The cornerstone of these efforts was the organization of over 200 in-person institutional investor meetings across prominent financial centers such as New York, Boston, San Francisco, San Diego, and various key European hubs.

The culmination of these efforts was the announcement on January 8, 2024, when Ambrx revealed a definitive agreement to be acquired by Johnson & Johnson for a total equity value of approximately $2.0 billion. This acquisition, marked by a remarkable 105% premium to Ambrx’s unaffected closing stock price on January 5, stands as a testament to the success of LifeSci’s holistic approach to investor relations. It’s a story of partnership, perseverance, and ultimately, shared success.

“LifeSci have been our trusted Investor Relations advisor since November 2022. They have strategically advised us through multiple inflection points, including an overhaul of our positioning & messaging, our transition from NYSE to NASDAQ, several data read-outs and our ultimate acquisition by J&J. LifeSci’s investor engagement is second to none, not only do they have deep institutional relationships that enabled us to access new investors, but they were able to gather invaluable feedback which was utilized to fine-tune positioning & messaging and make strategic adjustments. Access to LifeSci’s HNW individual & family office network improved our share price and liquidity. The KOL events that LifeSci hosted, were extremely well organized and well-attended; it was clear that showcasing third-party KOL validation was very well received by the buy-side & pharma. I have had an excellent experience with LifeSci’s Senior and dedicated team – I would not hesitate to recommend them to any executive seeking a true value-add partner, with expertise across capital markets, investor engagement and scientific and strategic communications.” – Dan O’Connor, CEO